March 30, 2020 07:26 AM EDTUpdated 07:37 AM

Merck and Bayer unveil the data behind their CV ‘success,’ underwhelming the industry

Four months after Merck announced a surprise Phase III success on the heart drug they gave Bayer $1 billion for, the full data is …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mer­ck and Bay­er un­veil the da­ta be­hind their CV ‘suc­cess,’ un­der­whelm­ing the in­dus­try